Winning with Neupro_Athina Eleftheriou

Views:
 
Category: Entertainment
     
 

Presentation Description

No description available.

Comments

Presentation Transcript

PowerPoint Presentation:

Communication on the many dimensions of Parkinson’s disease and RECOVER data are winning attention from neurologists. Find out how your colleagues are Winning with Neupro ® . Strictly for internal UCB use only. RTG-PRM-012539-032012 © UCB Pharma S.A. 2012. All rights reserved.

PowerPoint Presentation:

Strictly for internal UCB use only. RTG-PRM-012539-032012 Athina Eleftheriou Product specialist CNS Athens, Greece “The ‘Many Dimensions’ campaign differentiates Neupro ® from all other dopamine agonists. Depression is very significant to clinicians. Pain is another important area. Our data specifically addresses these dimensions of Parkinson’s disease. Because of the strength of our data, doctors are confident that when they prescribe Neupro ® , they are addressing the variety of symptoms their Parkinson’s patients’ experience. Focusing on the many dimensions of Parkinson’s disease truly helps me to make Neupro ® the first choice for doctors.” © UCB Pharma S.A. 2012. All rights reserved.

PowerPoint Presentation:

Reference Trenkwalder C, Kies B, Rudzinska M, et al; and RECOVER study group. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER) . Mov Disord . 2011;26(1):90-99. Indication Neupro ® is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy or in combination with levodopa , over the course of the disease through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or on-off fluctuations). Brief Important Safety Information Adverse drug reactions (ADRs) reported in more than 10% of patients with Parkinson’s disease treated with Neupro ® transdermal patch were nausea, vomiting, application site reactions, somnolence, dizziness, and headache. Adverse drug reactions (ADRs) reported in more than 10% of patients with Restless Legs Syndrome: nausea, application site reactions, asthenic conditions and headache. Neupro ® has been associated with somnolence, including excessive daytime somnolence and sudden sleep onset episodes. In isolated cases, “sudden onset of sleep” occurred while driving and resulted in motor vehicle accidents. Patients treated with dopamine agonists for treatment of Parkinson’s disease, including Neupro ®, have been reported as exhibiting signs of pathological gambling, increased libido, and hypersexuality , generally reversible upon reduction of the dose or treatment discontinuation. Contraindications: Magnetic resonance imaging or cardioversion . It is recommended to monitor blood pressure, especially at the beginning of treatment, due to the general risk of orthostatic hypotension associated with dopaminergic therapy. Hallucinations have been reported, and patients should be informed that hallucinations can occur. Please refer to the European SmPC for full prescribing information (revised August 2011) Study Design Data reflect a phase 3b, multicenter, multinational, double-blind, placebo-controlled, 2-arm trial (n=287) to evaluate the effect of the 24-hour transdermal delivery of rotigotine on the control of early morning motor function, sleep quality, nocturnal symptoms, and nonmotor symptoms in patients with idiopathic Parkinson’s disease. Patients were randomized to placebo (n=97) or rotigotine (n=190). Primary outcomes were change from baseline to end of maintenance in early morning Unified Parkinson’s Disease Rating Scale (UPDRS) Part III score and Parkinson’s Disease Sleep Scale (PDSS). Secondary outcomes were change from baseline to end of maintenance in Nocturnal Akinesia , Dystonia , and Cramps Score (NADCS) and number of nocturias . Strictly for internal UCB use only. RTG-PRM-012539-032012 © UCB Pharma S.A. 2012. All rights reserved.

PowerPoint Presentation:

Tell us how you are Winning with Neupro ® . Strictly for internal UCB use only. RTG-PRM-012539-032012 © UCB Pharma S.A. 2012. All rights reserved.

authorStream Live Help